menu
    • menu
    [{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ SAB Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ SAB Biotherapeutics"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Human Rho D Immune Globulin","moa":"IgG","graph1":"Dermatology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"SAB-185","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Immunoglobulin G 285-292","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"CSL Behring","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Chemokine-derived antifibrotic peptides","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Stem cell gene therapy","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Etranacogene dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":2.0499999999999998,"dosageForm":"","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Albutrepenonacog Alfa","moa":"Factor X","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Human C1 Esterase Inhibitor","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Hyperimmune immunoglobulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ National Institutes of Health"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Commonwealth of Australia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"V451","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ Commonwealth of Australia","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Commonwealth of Australia"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Apolipoprotein A-I [human]","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Apolipoprotein A-I [human]","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Etranacogene dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":2.0499999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":2.0499999999999998,"dosageForm":"Intravenous infusion","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"HCmed Innovations","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Human Plasma-derived Polyvalent Immunoglobulin G","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"CSL Behring \/ HCmed Innovations","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ HCmed Innovations"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Uniqure","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lyophilized Human C1-esterase","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Orsini Specialty Pharmacy","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Orsini Specialty Pharmacy"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Immune Globulin G","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":2.0499999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":2.0499999999999998,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by CSL Behring

    Menu

    CSL Behring

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Alpha1-Proteinase Inhibitor

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CSL Behring Expands Commitment to Alpha-1 Community with ZEMAIRA® 4- and 5-Gram Vials

                            Details : Zemaira is a human alpha1-proteinase inhibitor approved for augmentation and maintenance therapy in adults with Alpha-1 Antitrypsin Deficiency.

                            Brand Name : Zemaira

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 02, 2024

                            Lead Product(s) : Human Alpha1-Proteinase Inhibitor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etranacogene Dezaparvovec-drlb

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CSL Behring Announces the First Patient has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) ...

                            Details : Hemgenix (etranacogene dezaparvovec-drlb) is an AAV5 based gene therapy designed to deliver a copy of a gene encoding hFIX-Padua. Its single IV infusion results in cell transduction and increase in circulating Factor IX activity in patients with Hemophil...

                            Brand Name : Hemgenix

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 20, 2023

                            Lead Product(s) : Etranacogene Dezaparvovec-drlb

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etranacogene Dezaparvovec-drlb

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Uniqure

                            Deal Size : $2,050.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            uniQure Announces Achievement of $100 Million Milestone Related to Hemophilia B Gene Therapy

                            Details : The licensing agreement provided CSL Behring with exclusive global rights to Hemgenix (etranacogene dezaparvovec), uniQure’s first approved gene therapy for hemophilia B in the United States, EU and European Economic Area, and the UK, for patients with...

                            Brand Name : Hemgenix

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $450.0 million

                            June 20, 2023

                            Lead Product(s) : Etranacogene Dezaparvovec-drlb

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Uniqure

                            Deal Size : $2,050.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immune Globulin G

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefil...

                            Details : Hizentra (immune globulin subcutaneous [human] 20% liquid) supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents. It is indicated primary immunodeficiency and maintenance therapy in a...

                            Brand Name : Hizentra

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 18, 2023

                            Lead Product(s) : Immune Globulin G

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etranacogene Dezaparvovec-drlb

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Orsini Specialty Pharmacy

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Orsini Specialty Pharmacy Selected by CSL Behring as a Limited Distribution Partner for HEMGENIX®, the First ...

                            Details : Hemgenix (etranacogene dezaparvovec-drlb) is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B who Currently use Factor IX prophylaxis therapy, or Have current or historical life-threatening hemor...

                            Brand Name : Hemgenix

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 20, 2022

                            Lead Product(s) : Etranacogene Dezaparvovec-drlb

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Orsini Specialty Pharmacy

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lyophilized Human C1-esterase

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CSL Receives Manufacturing and Marketing Authorization in Japan for “Berinert S.C. Injection 2000,” as a M...

                            Details : In the COMPACT study, acute HAE attacks were significantly lower in the "Berinert"(Lyophilized Human C1-esterase) 60 IU/kg group at 0.52 per month compared to 4.03 per month in the placebo group (p<0.001, mixed model).

                            Brand Name : Berinert

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 26, 2022

                            Lead Product(s) : Lyophilized Human C1-esterase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etranacogene Dezaparvovec

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene D...

                            Details : Data from the largest gene therapy study in Hemophilia B to date shows that etranacogene dezaparvovec is statistically superior in reducing annualized bleeding rate compared to baseline FIX prophylactic therapy.

                            Brand Name : AMT-061

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 04, 2022

                            Lead Product(s) : Etranacogene Dezaparvovec

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etranacogene Dezaparvovec

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Uniqure

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvove...

                            Details : Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable FIX expression, assessed at 18 months following a single dose of AMT-061(etranacogene dezaparvovec).

                            Brand Name : AMT-061

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 09, 2021

                            Lead Product(s) : Etranacogene Dezaparvovec

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Uniqure

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Plasma-derived Polyvalent Immunoglobulin G

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : HCmed Innovations

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            HCmed Reaches Milestone in Immunoglobin Combination Product Development with CSL Behring

                            Details : CSL Behring partnered with HCmed to develop a combination product consisting of a plasma-derived immunoglobulin formulation (CSL787) administered via a customized version of the AdheResp nebulizer, HCmed's breath-actuated mesh nebulizer.

                            Brand Name : CSL787

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 24, 2021

                            Lead Product(s) : Human Plasma-derived Polyvalent Immunoglobulin G

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : HCmed Innovations

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CSL Behring

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etranacogene dezaparvovec

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Uniqure

                            Deal Size : $2,050.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            UniQure Announces Closing of Commercialization and License Agreement With CSL Behring

                            Details : uniQure announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for the global licensing agreement with CSL Behring for etranacogene dezaparvovec expired on May 5, 2021, and the agreement became fully effective on...

                            Brand Name : AMT-061

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $450.0 million

                            May 06, 2021

                            Lead Product(s) : Etranacogene dezaparvovec

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Uniqure

                            Deal Size : $2,050.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth